Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
December 2025
in “
Biomedicines
”
tyrosine kinase inhibitors lenvatinib vandetanib cabozantinib cutaneous adverse events hand-foot skin reaction xerosis alopecia acneiform eruptions VEGF EGFR keratinocyte dysfunction vascular fragility emollients keratolytics sun protection skin dryness hair loss skin rash vascular endothelial growth factor epidermal growth factor receptor moisturizers exfoliants sunscreen
Studysummary This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on mdpi.com →